Commodities

QIAGEN and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold Plus

QIAGEN N.V.














QGEN, -0.87%












(frankfurt prime standard:QIA) and Tecan Group
AG (six swiss exchange:TECN), a global leader in laboratory automation
and liquid handling technology, announced today a collaboration to
improve the processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus)
diagnostic test through the utilization of Tecan’s Fluent
[®]

Laboratory Automation workstation for the aliquoting of samples for the
optional Lithium Heparin single-tube workflow. The Fluent instruments
will be supplied directly to laboratories through Tecan’s Life Sciences
Business.

QIAGEN’s fourth-generation QuantiFERON-TB Gold Plus is the modern gold
standard for latent tuberculosis (TB) detection based on world leading
interferon gamma release assay (IGRA) technology.

QuantiFERON-TB Gold Plus offers customers the most flexible workflow
among latent TB screening tests, including a single-tube option that
enables efficient screening in large-scale programs by collecting blood
samples at patient sites and transporting them to labs for processing up
to 53 hours after venipuncture.

The two parties are working together to optimize a solution that
standardizes and automates the manual steps in liquid handling for the
aliquoting of samples. Customers will be able to leverage the
high-performance Fluent automation system and thereby achieve the goal
of significantly reducing hands-on time, providing greater ease of use
and ensure consistency in pre-analytic methods and thereby reducing
processing errors and variability between runs. Front-end automation
solutions also offer laboratories efficient automation of single tube
collection for QuantiFERON, and thereby create efficiency in the lab and
improve the patient blood collection experience.

Please find the full press release here

###

View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005610/en/

SOURCE: QIAGEN N.V.”>
<Property FormalName=”PrimaryTwitterHandle” Value=”@Qiagen

Investor Relations

John Gilardi
+49 2103 29 11711

Dr.
Sarah Fakih
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public
Relations

Dr. Thomas Theuringer
+49 2103 29 11826

Robert
Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Tecan
Group

Martin Braendle
Vice President, Communications &
Investor Relations
Tel. +41 (0) 44 922 84 30
email: investor@tecan.com
www.tecan.com

Copyright Business Wire 2019

Source

neallesh@yahoo.co.uk

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.